Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Albertsons' Q4 Earnings Beat Estimates, Pharmacy Sales Rise 18% Y/Y

In This Article:

Albertsons Companies, Inc. ACI reported fourth-quarter fiscal 2024 results, with the top line increasing year over year and surpassing the Zacks Consensus Estimate. The bottom line declined year over year but beat the consensus mark. 

The company delivered solid results in the fiscal fourth quarter, closing fiscal 2024 with positive momentum and continued investment in the Customers for Life strategy. This strategy has positioned it for future growth and value creation. Looking ahead, the focus will be on investments in the core business, including growth in digital platforms and the Albertsons Media Collective. While fiscal 2025 will be an investment year, growth is expected to align with long-term goals starting in fiscal 2026.

Albertsons Companies, Inc. Price, Consensus and EPS Surprise

Albertsons Companies, Inc. price-consensus-eps-surprise-chart | Albertsons Companies, Inc. Quote

Albertsons’ Quarterly Performance: Key Insights

Albertsons posted adjusted quarterly earnings of 46 cents per share, which surpassed the Zacks Consensus Estimate of 40 cents. However, the bottom line declined 14.8% from 54 cents per share reported in the prior-year period. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)

Net sales and other revenues of $18,799.5 million were above the Zacks Consensus Estimate of $18,627 million and rose 2.5% year over year. The year-over-year increase in the top line stemmed from a 2.3% increase in identical sales, with 18% increase in pharmacy sales serving as the main contributor. Digital sales grew 24% due to strong growth in first party sales.

Loyalty membership grew 15% to reach 45.6 million in the fourth quarter of fiscal 2024 compared with the same period in fiscal 2023.

Insight Into ACI's Margins & Expenses

The gross profit of $5.1 billion increased 0.1% year over year. However, the gross margin contracted 60 basis points (bps) year over year to 27.4% compared with 28% in the fourth quarter of fiscal 2023.

Excluding the impacts of fuel and LIFO expenses, the gross margin rate decreased 45 bps year over year. This decrease was primarily due to strong growth in pharmacy sales, which typically have a lower gross margin rate, and increased delivery and handling costs associated with rise in digital sales, partially offset by productivity initiatives. In the fourth quarter of fiscal 2024, incremental investments were also made in the customer value proposition, funded by benefits from productivity initiatives, including reduced shrink expenses.

In the fourth quarter, selling and administrative expenses jumped 2.5% to $4.8 billion and remained unchanged at 25.7% as a percentage of net sales and other revenues. Excluding the impact of fuel, the selling and administrative expense rate rose five bps year over year. This reduction was primarily due to lower merger-related costs and the leveraging of employee costs as well as depreciation and amortization, partially offset by higher business transformation costs. Continued productivity initiatives also contributed to lower selling and administrative expenses.

Adjusted EBITDA declined 6.6% year over year to $855.1 million while the adjusted EBITDA margin was 4.5%, down 50 bps year over year.